Isabella Lurje

12PUBLICATIONS
60CO-AUTHORS
Deep learningPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical biochemistry - lipidsTe whai wāhi ākonga me ngā mahi whakaako o te Māori (Māori student engagement and teaching)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 17, 2026
Counterfactual Diffusion Models Provide Interpretable Explanations of Artificial Intelligence Models in Pathology.

|Jun 03, 2026
TERT rs10069690 variant is linked to reduced cholangiocarcinoma incidence but adverse prognosis in patients undergoing resection.

|Apr 04, 2025
Letter: Comparing the Efficacy of Adjuvant PD-1 Inhibitor After Curative Resection for Metabolic Dysfunction-Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies-Authors' Reply.

Isabella Lurje, Deniz Uluk, Frank Tacke

|Feb 18, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma.

Deniz Uluk, Justus Pein, Sophia Herda

|Dec 13, 2024
Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.

Isabella Lurje, Frank Tacke

|Nov 09, 2024
High Expression of the Tumor Suppressor Protein ITIH5 in Cholangiocarcinomas Correlates with a Favorable Prognosis.

Verena J Dreyer, Jia-Xin Shi, Michael Rose

Pageof 2

Frequent Collaborators

9 joint publications

Frank Tacke

8 joint publications

Georg Lurje

3 joint publications

Zoltan Czigany

3 joint publications

Deniz Uluk